MetaADEDB 2.0 @ LMMD
ramosetron
(NTHPAPBPFQJABD-LLVKDONJSA-N)
Structure
SMILES
O=C(c1cn(c2c1cccc2)C)[C@@H]1CCc2c(C1)[nH]cn2
Type(s)
Investigational
Molecular Formula:
C17H17N3O
Molecular Weight:
279.336
Log P:
2.8892
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
1
TPSA:
50.68
CAS Number(s):
132036-88-5
Synonym(s)
1.
ramosetron
2.
5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazol
3.
Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)-
4.
Nasea
5.
YM 060
6.
YM-060
7.
YM060
8.
ramosetron hydrochloride
External Link(s)
MeSHC071315
PubChem Compound108000
135418340
BindingDB50334454
ChEBI135156
CHEMBLCHEMBL1643895
DrugBankDB09290
DrugCentral2357
IUPHAR/BPS Guide to PHARMACOLOGY2301
KEGGdr:D08466
Therapeutic Target DatabaseD06EEE
D0RA9E
ZINC5116719
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Alanine Aminotransferase IncreasedOFFSIDES
2Altered state of consciousnessOFFSIDES
3Anal abscessOFFSIDES
4AnorexiaOFFSIDES
5ApathyOFFSIDES
6Blood albumin decreasedOFFSIDES
7Blood lactate dehydrogenase increasedOFFSIDES
8Blood potassium increasedOFFSIDES
9Blood pressure immeasurableOFFSIDES
10Blood uric acidOFFSIDES
11Bone marrow depressionOFFSIDES
12BradycardiaOFFSIDES
13Brain ContusionOFFSIDES
14Cancer PainOFFSIDES
15CarcinomaOFFSIDES
16Central line infectionOFFSIDES
17CholangiolitisOFFSIDES
18Cholecystitis infectiveOFFSIDES
19Chronic ulcerative colitisOFFSIDES
20CyanosisOFFSIDES
21Cystitis viralOFFSIDES
22Cytomegalovirus enterocolitisOFFSIDES
23Depressed Level of ConsciousnessOFFSIDES
24Diarrhea10446763CTD
25Disseminated Intravascular CoagulationOFFSIDES
26Drug withdrawal headacheOFFSIDES
27Duodenal perforationOFFSIDES
28DysgeusiaOFFSIDES
29Engraftment syndromeOFFSIDES
30EpilepsyOFFSIDES
31Febrile NeutropeniaOFFSIDES
32Fungus serology test positiveOFFSIDES
33Gastrointestinal perforationOFFSIDES
34Glioblastoma MultiformeOFFSIDES
35Granulocyte count decreasedOFFSIDES
36Hepatitis AOFFSIDES
37HepatitisOFFSIDES
38Infective spondylitisOFFSIDES
39Intestinal ObstructionOFFSIDES
40Irritable Bowel Syndrome17652911
23330973		CTD
41Leukopenia neonatalOFFSIDES
42Lymphocyte count decreasedOFFSIDES
43Lymphocyte stimulation test positiveOFFSIDES
44Malignant ascitesOFFSIDES
45Malignant neoplasm progressionOFFSIDES
46Narcotic intoxicationOFFSIDES
47NauseaOFFSIDES
48Neutrophil count decreasedOFFSIDES
49Optic NeuropathyOFFSIDES
50PallorOFFSIDES
51Performance status decreasedOFFSIDES
52Pericardial effusionOFFSIDES
53PericarditisOFFSIDES
54PneumothoraxOFFSIDES
55Portal Vein ThrombosisOFFSIDES
56Protein total decreasedOFFSIDES
57Pyoderma GangrenosumOFFSIDES
58Retinoic acid syndromeOFFSIDES
59RhinorrheaOFFSIDES
60Scan with contrast abnormalOFFSIDES
61SequestrectomyOFFSIDES
62StridorOFFSIDES
63Vomiting16319109CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.